Clinical Trial

Early Warning System for Allergic Rhinitis in the MASK-air® App

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2025 (before its estimated January 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective consists in the comparison of the combined symptom medication score values between (i) patients randomised to the early warning system personalised forecasting messages, and (ii) patients randomised to generic messages already delivered by MASK-air®. The combined symptom medication score has recently been developed in a data-driven way and validated (https://eaaci.org/images/CSMS.pdf); it assesses allergic rhinitis control taking into account both reported symptoms and medication use. As secondary objectives, visual analogue scales on allergic rhinitis symptoms (VAS global, nasal, eye, asthma), and medication use will also be separately compared.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-06.
Trial Details
NCT Number NCT06768736
Lead Sponsor Universidade do Porto
Collaborators: Centro Hospitalar De São João, E.P.E.
Conditions Allergic Rhinitis
Enrollment 210 participants
Start Date 2025-01-30
Primary Completion 2026-01-15 (estimated)
Study Completion 2026-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-02-06